Analysts expect AngioDynamics, Inc. (NASDAQ:ANGO) to post $0.21 earnings per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for AngioDynamics’ earnings. AngioDynamics posted earnings per share of $0.19 during the same quarter last year, which would indicate a positive year-over-year growth rate of 10.5%. The company is scheduled to announce its next earnings results on Tuesday, July 17th.
According to Zacks, analysts expect that AngioDynamics will report full-year earnings of $0.74 per share for the current fiscal year. For the next financial year, analysts forecast that the firm will report earnings of $0.93 per share, with EPS estimates ranging from $0.90 to $0.95. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that cover AngioDynamics.
AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings results on Thursday, March 29th. The medical instruments supplier reported $0.25 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.20 by $0.05. The firm had revenue of $83.85 million for the quarter, compared to the consensus estimate of $86.13 million. AngioDynamics had a return on equity of 5.11% and a net margin of 0.97%.
Shares of ANGO stock traded up $0.11 on Monday, reaching $18.99. The stock had a trading volume of 36,910 shares, compared to its average volume of 262,137. The company has a market cap of $694.87, a P/E ratio of 26.01, a price-to-earnings-growth ratio of 1.70 and a beta of 1.00. AngioDynamics has a 1 year low of $14.80 and a 1 year high of $19.25. The company has a debt-to-equity ratio of 0.16, a current ratio of 2.88 and a quick ratio of 1.84.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Fenimore Asset Management Inc. lifted its position in AngioDynamics by 0.6% during the fourth quarter. Fenimore Asset Management Inc. now owns 594,490 shares of the medical instruments supplier’s stock valued at $9,886,000 after purchasing an additional 3,715 shares in the last quarter. First Trust Advisors LP lifted its position in AngioDynamics by 13.7% during the fourth quarter. First Trust Advisors LP now owns 32,866 shares of the medical instruments supplier’s stock valued at $547,000 after purchasing an additional 3,968 shares in the last quarter. Legal & General Group Plc lifted its position in AngioDynamics by 7.0% during the third quarter. Legal & General Group Plc now owns 65,557 shares of the medical instruments supplier’s stock valued at $1,119,000 after purchasing an additional 4,296 shares in the last quarter. Highbridge Capital Management LLC lifted its position in AngioDynamics by 21.4% during the third quarter. Highbridge Capital Management LLC now owns 25,304 shares of the medical instruments supplier’s stock valued at $432,000 after purchasing an additional 4,461 shares in the last quarter. Finally, BNP Paribas Arbitrage SA lifted its position in AngioDynamics by 50.9% during the third quarter. BNP Paribas Arbitrage SA now owns 21,329 shares of the medical instruments supplier’s stock valued at $365,000 after purchasing an additional 7,194 shares in the last quarter. Institutional investors own 97.09% of the company’s stock.
AngioDynamics Company Profile
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.